India on Pfizer Covid vaccine: In touch with all manufacturers

potential coronavirus vaccine to enter human trials


The Indian government is in dialogue with all vaccine manufacturers including foreign ones about a coronavirus vaccine, the country’s health ministry said Tuesday in the context of Pfizer reporting encouraging results for its candidate.

Asked whether India was considering tie-up with US-based Pfizer Inc for their Covid vaccine candidate, the country’s health secretary Rakesh Bhushan said: “The national expert group on Covid vaccine administration is in dialogue with all vaccine manufacturers including domestic and foreign manufacturers. During this dialogue, we look at the status of development of their vaccines and also at regulatory approvals where have they progressed.”

On the infrastructure to support the storage and carriage of Covid vaccines, Bhushan said the government was also engaged in discussion regarding logistical requirements of the vaccines if they are required to be stored at temperatures as low as minus 90 degrees.

We are in a position to not only augment and strengthen but also add to our cold chain capabilities. However, we currently don’t have those numbers to share. Any such large scale immunization would require a substantial increase in cold chain points but also increase in cold chain equipment including walk-in coolers, deep freezers and refrigerated vans,” he added.

Last week, the health ministry had informed that the country has more than 28,000 cold chain points, 700-plus refrigerator vans and more than 70,000 vaccinators to assist in the vaccine administration.

We have already utilized them under the universal immunization program and would be used in administration of Covid vaccination as well,” Bhushan had stated earlier.

A day ago, Pfizer Inc and German biotech company BioNTech had announced that their Covid vaccine candidate, BNT162b2, demonstrated efficacy of 90 percent in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.

The vaccine manufacturer had also stated that they expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

Many vaccine candidates are already in final-stage testing across the world for Covid-19. An experimental vaccine developed by Britain’s AstraZeneca is among the most advanced ones, and Britain expects to roll it out in late December or early 2021.

AstraZeneca’s vaccine, originally developed by the Oxford University, is undergoing trials in India in partnership with Serum Institute of India.

Other late-stage vaccines are developed by Moderna Inc, Pfizer Inc with partner BioNTech SE, and Johnson & Johnson.

Last week, a Reuters report quoting a senior Indian government official said India’s own Bharat Biotech, a private company that is developing Covaxin with the government-run Indian Council of Medical Research (ICMR), could make available its vaccine by February.